Advertisement
U.S. markets closed

Acasti Pharma Inc. (ACST)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.4350+0.0900 (+2.69%)
At close: 03:58PM EST
3.3200 -0.12 (-3.35%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.3450
Open3.4000
Bid3.0000 x 3000
Ask3.4500 x 1000
Day's Range3.3550 - 3.4500
52 Week Range1.7200 - 3.8400
Volume11,370
Avg. Volume28,903
Market Cap32.287M
Beta (5Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-5.6800
Earnings DateFeb 12, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ACST

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Acasti Pharma, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/28/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

    Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA)Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, On Track for NDA Submission TimelinePoster Highlighting the STRIVE-ON Trial Presented at 2024 International Stroke Conference PRINCETON, N.J., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its n

  • GlobeNewswire

    Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

    Accepted for Presentation at the 2024 International Stroke ConferencePRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that a poster outlining its pivotal Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405) has been a

  • Simply Wall St.

    Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...